Specialized expertise and customized solutions across 14 therapeutic centers of excellence, including oncology, GI/NASH, pediatrics, neurology and rare diseases.
Biosimilars in the U.S. have begun to fulfill their promise of generating savings for the healthcare system by reducing the cost of biologics. However, many studies and reports have highlighted issues within the current system that can lead to sub-optimal uptake of biosimilars and put the long-term sustainability of biosimilars at risk. Understanding these issues with case studies and examples is critical if biosimilars are to continue playing a crucial role in the overall health system.
This report intends to create a base of foundational analytics to better understand the dynamics of biosimilars. The focus of this report is on infused biosimilars that fall under the buy and bill program in Medicare Part B. In particular, the aim is to understand the key issues that can lead to the sub-optimal functioning of the biosimilars market in the U.S. by analyzing various case studies.
Specialized expertise and customized solutions across 14 therapeutic centers of excellence, including oncology, GI/NASH, pediatrics, neurology and rare diseases.
Bring your biosimilar to market faster by tapping into unparalleled data, technology, advanced analytics, and scientific expertise.